PARKERVISION INC 424B Filings

ParkerVision, Inc. is updating a resale registration covering up to 16,638,353 shares of common stock issuable upon conversion of 2022 convertible notes at a fixed price of $0.13 per share.

For the quarter ended June 30, 2026, ParkerVision reported no licensing revenue but recorded net income of $148,000, largely from a favorable $1.7 million change in the fair value of contingent payment obligations. For the first six months of 2026, it posted a net loss of $1.4 million and used $1.7 million of cash in operations.

Cash and cash equivalents were $2.5 million and working capital was about $0.8 million, against total liabilities of $48.3 million and a shareholders’ deficit of $44.6 million. Management states there is substantial doubt about the company’s ability to continue as a going concern over the next year, given dependence on uncertain patent-enforcement proceeds, significant secured contingent payment obligations with fair value of $39.0 million (underlying note balance roughly $71.5 million), $5.8 million of unsecured contingent obligations, and $2.3 million of convertible notes, including $1.1 million maturing within 12 months.

ParkerVision, Inc. registered for resale up to 1,578,946 shares of common stock held by a selling stockholder, including 526,315 shares issuable upon warrant exercise. The company will not receive proceeds from share resales and would receive up to $526,315 only if the warrants are exercised for cash, for general working capital and litigation expenses.

For the quarter ended June 30, 2026, ParkerVision reported no licensing revenue and net income of $148,000, with a six‑month net loss of $1.4 million. Cash and cash equivalents were $2.5 million and working capital was about $0.8 million, while total liabilities were $48.3 million against $3.7 million of assets, resulting in a shareholders’ deficit of $44.6 million.

The company records large secured contingent payment obligations at fair value of $39.0 million and unsecured contingent payment obligations of $5.8 million, tied to future patent‑related proceeds. Management discloses substantial doubt about its ability to continue as a going concern over the next year, citing dependence on uncertain litigation and licensing outcomes, behavior of convertible note holders, and access to additional financing.

ParkerVision, Inc. registered for resale up to 13,342,953 shares of common stock, including shares issued in prior securities purchase agreements, shares underlying 1,619,289 warrants, and shares issued for services. Selling stockholders receive sale proceeds; ParkerVision would receive up to $2,833,756 only if the warrants are exercised for cash, which it plans to use for working capital and litigation expenses.

For the quarter ended June 30, 2026, ParkerVision reported no licensing revenue and net income of $148,000, driven mainly by a favorable $1.7 million change in fair value of contingent payment obligations, while the six‑month period showed a net loss of $1.4 million. Cash was $2.5 million with working capital of $0.8 million and an accumulated deficit of $457.0 million, alongside large fair‑value liabilities for secured ($39.0 million) and unsecured ($5.8 million) contingent payment obligations. Management discloses substantial doubt about the company’s ability to continue as a going concern over the next year.

ParkerVision, Inc. is filing a prospectus supplement covering resale of up to 5,871,584 shares of common stock by selling stockholders; the company will not receive proceeds from these sales. The supplement incorporates the June 30, 2026 Form 10-Q.

ParkerVision licenses wireless RF technologies and pursues patent-enforcement litigation as its primary business model. For the first half of 2026 it reported a net loss of $1.4 million and no licensing revenue, with cash used in operations of $1.7 million. Cash and cash equivalents were $2.5 million and working capital was about $0.8 million, against a shareholders’ deficit of $44.6 million.

The balance sheet is dominated by fair-valued contingent payment obligations tied to litigation proceeds, including $39.0 million secured and $5.8 million unsecured obligations. Management discloses substantial doubt about the company’s ability to continue as a going concern over the next year absent successful licensing, favorable note-holder behavior, cost control, and/or new financing.

ParkerVision, Inc. registered for resale by selling stockholders up to 16,809,295 shares of common stock, including shares issuable upon conversion of convertible notes and exercise of warrants. The company will not receive proceeds from these resales, but could receive up to $3.9 million in gross proceeds if Aspire and Tailwinds warrants are exercised for cash, to be used for general working capital and corporate purposes.

For the quarter ended June 30, 2026, ParkerVision reported net income of $148,000 and a six‑month net loss of $1.4 million, with $2.5 million in cash and cash equivalents and an accumulated deficit of $457.0 million. Fair value of secured and unsecured contingent payment obligations totaled $44.8 million, and management disclosed substantial doubt about the ability to continue as a going concern given limited working capital, upcoming convertible debt maturities, and dependence on uncertain patent‑enforcement proceeds.

ParkerVision, Inc. has registered for resale by existing holders up to 18,014,164 shares of common stock, including shares issuable upon conversion of prior convertible notes, for services and upon exercise of a consulting warrant. The company will not receive proceeds from stockholder resales, but could receive up to $180,000 in cash if the consulting warrant is exercised, which would be used for general working capital and corporate purposes.

For the quarter ended June 30, 2026, ParkerVision reported net income of $148,000, but a six‑month net loss of $1.4 million and operating cash outflows of $1.7 million. Cash and cash equivalents were $2.5 million, with total assets of $3.7 million versus total liabilities of $48.3 million, resulting in a shareholders’ deficit of $44.6 million. Management discloses substantial doubt about the company’s ability to continue as a going concern over the next year, given recurring losses, limited liquidity, and $2.3 million of convertible notes, of which $1.1 million is current, plus large secured and unsecured contingent payment obligations tied to future patent-enforcement proceeds.

ParkerVision, Inc. filed a prospectus supplement covering the resale by existing holders of up to 17,189,660 shares of common stock previously registered under multiple shelf and Form S-1 registration statements. The company will not receive proceeds from these resales, but could receive up to $700,000 from cash exercises of a 2016 warrant and up to $1,763,500 from share and warrant sales under the Aspire Capital agreement, which it expects to use for patent enforcement, working capital, and general corporate purposes.

For the quarter ended June 30, 2026, ParkerVision reported net income of $148,000, driven largely by a $1.7 million gain from remeasuring contingent payment obligations, while posting a six‑month net loss of $1.4 million. Cash and cash equivalents were $2.5 million, working capital was about $0.8 million, and the company reported a shareholders’ deficit of $44.6 million with an accumulated deficit of $457.0 million. Management discloses that substantial doubt exists about its ability to continue as a going concern absent successful patent licensing outcomes, favorable behavior from convertible note holders, and/or new debt or equity financing.

ParkerVision, Inc. filed a prospectus supplement updating a resale registration that permits selling stockholders to resell up to 12,800,000 shares of common stock, including shares issuable from convertible notes and a five-year warrant. The company is not selling shares and will only receive cash if the warrant is exercised, up to $800,000, which it plans to use for patent enforcement, working capital, and general corporate purposes.

Attached financials for the quarter ended June 30, 2026 show cash of $2.5 million, working capital of about $0.8 million, a six‑month net loss of $1.4 million, and an accumulated deficit of $457.0 million. Large fair‑valued obligations include a secured contingent payment obligation of $39.0 million and unsecured contingent obligations of $5.8 million. Management states there is substantial doubt about the company’s ability to continue as a going concern over the next year absent successful licensing outcomes and/or new financing.

ParkerVision, Inc. files a Prospectus Supplement registering 9,387,500 shares of Common Stock for resale by the selling shareholders. The registered shares consist of 2,843,750 issued shares, 6,343,750 shares issuable upon conversion of Convertible Notes at a fixed conversion price of $0.16 per share, and 200,000 shares issuable upon exercise of Options. The company will not receive proceeds from resale by the selling shareholders; if the Options are exercised for cash, the company could receive up to $42,620 in gross proceeds. This supplement updates the Prospectus with information furnished on May 21, 2026.

ParkerVision, Inc. registers 16,638,353 shares of Common Stock for resale by selling shareholders.

The shares are issuable upon conversion of convertible promissory notes dated between May 10, 2022 and August 3, 2022 at a fixed conversion price of $0.13 per share. This Prospectus Supplement (dated May 21, 2026) supplements the Prospectus dated August 22, 2022 and attaches a Form 8-K furnished on May 21, 2026. The resale registration covers shares held by the selling shareholders named in the Prospectus.

ParkerVision, Inc. files a Prospectus Supplement registering 1,578,946 shares of Common Stock for resale by a selling stockholder.

The registration covers an aggregate of 1,052,631 shares and 526,315 shares underlying warrants issued under a December 14, 2021 agreement. The company will not receive proceeds from resales; if the Warrants are exercised for cash, ParkerVision would receive up to $526,315, which it expects to use for general working capital, including payment of litigation expenses. The supplement attaches a Form 8-K disclosing that director Lewis Titterton resigned effective May 15, 2026 and that Anthony Bowers was appointed to the Board and its Audit and Compensation Committees on May 19, 2026.

ParkerVision, Inc. is updating a resale prospectus to register 13,342,953 shares of Common Stock for resale by selling stockholders under the Prospectus Supplement dated May 21, 2026. The shares consist of several issuances, including 7,962,722 shares issued under earlier purchase agreements, 3,230,942 shares plus 1,619,289 shares underlying warrants, and 530,000 shares issued for services.

The company states it will not receive proceeds from resale of the registered shares; however, if the Warrants are exercised for cash, the company would receive up to $2,833,756, which it expects to use for general working capital, including payment of litigation expenses. The supplement attaches a Form 8-K that discloses a director resignation on May 15, 2026 and the appointment of a new director on May 19, 2026. The company’s common stock trades on the OTCQB under the symbol PRKR.

ParkerVision, Inc. registers 5,871,584 shares of Common Stock for resale by selling stockholders under a Prospectus Supplement dated May 21, 2026. The company will not receive proceeds from these resales. The supplement attaches a Form 8-K filed May 21, 2026, which furnishes a press release.

The Form 8-K discloses a director resignation and board appointment: May 15, 2026 resignation of Lewis Titterton (retirement) and appointment of Anthony Bowers on May 19, 2026, who joins the Audit and Compensation Committees and will receive standard non-employee director compensation and the company’s standard indemnification agreement.

ParkerVision, Inc. files a prospectus supplement registering 16,809,295 shares of Common Stock for resale by selling stockholders under its April 28, 2020 prospectus. The supplement notes the company will not receive proceeds from those resales; cash proceeds up to $3,900,000 may result if certain warrants are exercised.

The filing also furnishes a Form 8-K reporting the resignation of director Lewis Titterton due to retirement and the Board's appointment of Anthony Bowers to fill the vacancy and to serve on the Audit and Compensation Committees.

ParkerVision, Inc. files a prospectus supplement registering 18,014,164 shares of Common Stock for resale by selling stockholders.

The shares comprise convertible-note conversions, consulting issuances and a warrant; the company will not receive proceeds from resales, except it would receive up to $180,000 if the Park Consulting Warrant is exercised for cash. The supplement incorporates an attached Form 8-K describing a director resignation and appointment.

ParkerVision, Inc. filed a prospectus supplement registering 17,189,660 shares of Common Stock for resale by selling stockholders pursuant to prior registration statements.

The supplement confirms the company will not receive proceeds from resales, although it may receive proceeds from certain warrant exercises (up to $700,000 and up to $1,763,500 related to Aspire Capital arrangements). The supplement also furnishes a Form 8-K reporting a director resignation and appointment.

ParkerVision, Inc. files a Prospectus Supplement registering 12,800,000 shares of Common Stock for resale by selling stockholders, consisting of up to 7,800,000 shares issuable upon conversion of convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant. The company will not receive proceeds from resales by selling stockholders; if the warrant is exercised for cash, the company would receive up to $800,000 in gross proceeds to fund patent enforcement actions and for working capital. This supplement incorporates an attached Form 8-K that discloses a director resignation and a new director appointment.

ParkerVision, Inc. registers 9,387,500 shares of Common Stock for resale by selling shareholders as set forth in the prospectus supplement dated May 7, 2026.

The prospectus supplement states the company will not receive proceeds from resales by the selling shareholders; if the 200,000 Options are exercised for cash, the company would receive up to $42,620 in gross proceeds to be used for general working capital purposes. As of May 1, 2026, 147,767,649 shares of common stock were outstanding.

ParkerVision, Inc. registers the resale of up to 16,638,353 shares of Common Stock issuable upon conversion of convertible promissory notes with a fixed conversion price of $0.13 per share. This supplement attaches the company's Form 10-Q filed May 7, 2026.

The 10-Q shows cash and cash equivalents of $3.4 million, an accumulated deficit of $457.2 million, and a secured contingent payment obligation measured at fair value of $40.1 million. Shares outstanding were 147,767,649 as of May 1, 2026. The 10-Q also discloses substantial doubt about the company’s ability to continue as a going concern for the next twelve months.

ParkerVision, Inc. files a prospectus supplement registering 1,578,946 shares of common stock for resale by a selling stockholder. The registration covers 1,052,631 shares and 526,315 shares underlying warrants issued under a December 14, 2021 agreement. The company will not receive proceeds from the resale; however, if the 526,315 Warrants are exercised for cash, the company would receive up to $526,315 in gross proceeds to be used for general working capital, including litigation expenses. Shares outstanding were 147,767,649 as of May 1, 2026. This supplement updates the prospectus with the company’s Form 10-Q for the quarter ended March 31, 2026.

ParkerVision, Inc. filed a Prospectus Supplement dated May 7, 2026 registering the resale of 13,342,953 shares of Common Stock under a prior prospectus. The supplement states the company will not receive proceeds from sales by the selling stockholders; however, if underlying warrants are exercised for cash, the company would receive up to $2,833,756 in gross proceeds.

The supplement attaches the company’s Form 10-Q for the quarter ended March 31, 2026, which shows cash of $3.4 million, a net loss for the quarter of $1.553 million, and total secured contingent payment obligations measured at fair value of $40.144 million. Shares outstanding were 147,767,649 as of May 1, 2026. The filing reiterates substantial litigation-driven operations, contingent payment obligations tied to patent proceeds, and management’s statement of substantial doubt about going concern for the next year.

ParkerVision, Inc. files a Prospectus Supplement registering 5,871,584 shares of common stock for resale by selling stockholders. The supplement attaches ParkerVision’s Form 10-Q for the quarter ended March 31, 2026 and states the company will not receive proceeds from these resales.

The Form 10-Q shows $3.4 million in cash, a net loss of $1.553 million for the three months ended March 31, 2026, secured contingent payment obligations of $40.144 million, and 147,767,649 shares outstanding as of May 1, 2026. The filing discloses substantial doubt about the company’s ability to continue as a going concern for one year.

ParkerVision, Inc. filed a Prospectus Supplement dated May 7, 2026 registering 16,809,295 shares of Common Stock for resale by selling stockholders. The registration covers listed conversion shares, private-offering issuances, shares issued for services/repayments, and up to warrants exercisable for up to 5,200,000 shares.

The company will not receive proceeds from resales by selling stockholders; however, it would receive up to $3,900,000 if the Aspire and Tailwinds warrants are exercised for cash. The supplement incorporates ParkerVision’s Form 10-Q for the quarter ended March 31, 2026, which shows cash of $3.4M, an accumulated deficit of $457.2M, a secured contingent payment obligation measured at $40.144M, and shares outstanding of 147,767,649 as of May 1, 2026. The 10-Q also discloses substantial doubt about the company’s ability to continue as a going concern for one year.

ParkerVision, Inc. files a Prospectus Supplement registering 18,014,164 shares of common stock for resale by selling stockholders, as described in the Prospectus Supplement dated May 7, 2026. The registration covers (i) up to 5,457,583 shares issuable upon conversion of Tranche 1 Notes at a fixed conversion price of $0.10 per share, (ii) up to 10,131,581 shares issuable upon conversion of Tranche 2 Notes at a fixed conversion price of $0.08 per share, (iii) up to 625,000 shares issued for services under the Fisher Consulting Agreement, and (iv) up to 1,800,000 shares issuable upon exercise of a five-year Park Consulting Warrant with an exercise price of $0.10 per share. The company will not receive proceeds from sales by the selling stockholders; however, if the Park Consulting Warrant is exercised for cash, ParkerVision would receive up to $180,000 in gross proceeds.

Context: shares outstanding were 147,767,649 as of May 1, 2026. The supplement attaches the registrant's Form 10-Q for the quarter ended March 31, 2026.

ParkerVision filed a Prospectus Supplement registering 17,189,660 shares of common stock for resale by selling stockholders under previously filed registration statements. The supplement attaches the company's Form 10-Q for the quarter ended March 31, 2026 and notes that the company will not receive proceeds from selling stockholders' resales. The company may receive proceeds only if certain warrants are exercised (including up to $700,000 from the 2016 Warrant and potential proceeds related to the Aspire PIPE arrangements); any proceeds received are expected to be used to fund patent enforcement actions and for working capital.

ParkerVision, Inc. files a prospectus supplement updating its April 19, 2019 prospectus to register the resale of 12,800,000 shares of Common Stock, consisting of up to 7,800,000 shares issuable upon conversion of convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant. The company will not receive proceeds from resale by selling stockholders; to the extent the warrant is exercised for cash, the company would receive up to $800,000, which it expects to use for patent enforcement actions and general corporate purposes.

The supplement incorporates ParkerVision's Form 10-Q for the quarter ended March 31, 2026, which shows cash and cash equivalents of $3.4 million, a net loss of $1.553 million for the quarter, and a secured contingent payment obligation carried at fair value of $40.144 million. Shares outstanding were 147,767,649 as of May 1, 2026. The company discloses substantial doubt about its ability to continue as a going concern for one year absent licensing proceeds, conversions/extensions of convertible notes, or additional financing.

ParkerVision, Inc. files a prospectus supplement updating a resale registration that permits the resale of 9,387,500 shares of Common Stock. The registered shares consist of (i) 2,843,750 shares issued under purchase agreements, (ii) 6,343,750 shares issuable on conversion of convertible notes with a fixed conversion price of $0.16 per share, and (iii) 200,000 shares issuable upon exercise of options. The company states it will not receive proceeds from selling shareholders; however, it may receive up to $42,620 if the 200,000 Options are exercised for cash. The supplement also attaches a Form 8-K disclosing that the Compensation Committee extended the expiration dates of existing, fully vested nonqualified stock options for the CEO (2,660,000 options) and CFO (870,550 options) from August 7, 2026 to August 7, 2029, with no change to exercise price ($0.171) or share counts and an expected one-time non-cash share-based compensation charge of approximately $360,000.

ParkerVision, Inc. files a Prospectus Supplement registering 16,638,353 shares of Common Stock for resale by selling shareholders, consisting of shares issuable upon conversion of convertible promissory notes dated between May 10, 2022 and August 3, 2022 with a fixed conversion price of $0.13 per share. The supplement incorporates an attached Form 8-K dated April 22, 2026. The 8-K discloses that the Compensation Committee approved an extension of expiration dates for certain fully vested nonqualified stock options granted on August 7, 2019—2,660,000 options for CEO Jeffrey Parker and 870,550 options for CFO Cynthia French—moving the expiration from August 7, 2026 to August 7, 2029. The company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 related to that modification.

ParkerVision, Inc. is updating its resale prospectus to cover 1,578,946 shares of Common Stock available for resale by a selling stockholder, consisting of 1,052,631 shares and 526,315 shares issuable upon exercise of related warrants. The company will not receive proceeds from the resale; if the Warrants are exercised for cash, the company would receive up to $526,315. The supplement attaches a Form 8-K filed April 27, 2026 and also discloses that the Compensation Committee extended certain executive stock options' expiration dates to August 7, 2029, with an expected one-time non-cash share-based charge of approximately $360,000.

ParkerVision, Inc. files a Prospectus Supplement registering 13,342,953 shares of Common Stock for resale by selling stockholders under its shelf prospectus. The supplement states the company will receive no proceeds from resales; cash proceeds up to $2,833,756 are possible if outstanding warrants are exercised.

The filing also attaches a Form 8-K disclosing that the Compensation Committee extended expiration dates for previously issued, fully vested nonqualified stock options for CEO Jeffrey Parker (2,660,000 options) and CFO Cynthia French (870,550 options) from August 7, 2026 to August 7, 2029. The exercise price remains $0.171 per share. The company expects a one-time non-cash share-based compensation charge of approximately $360,000.

ParkerVision, Inc. files a Prospectus Supplement registering 5,871,584 shares of Common Stock for resale by selling stockholders. The supplement attaches a Form 8-K reporting that on April 22, 2026 the Compensation Committee extended the expiration dates of previously granted, fully vested nonqualified stock options held by CEO Jeffrey Parker (2,660,000 options) and CFO Cynthia French (870,550 options) from August 7, 2026 to August 7, 2029 with no change to exercise price ($0.171) or share counts. The company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 related to the modification. The resale proceeds will not be received by the company.

ParkerVision, Inc. registers 16,809,295 shares of Common Stock for resale under a prospectus supplement dated April 27, 2026.

The supplement states the 16,809,295 shares consist of convertible-note conversions, prior private placements, shares issued for services and payables, and warrants, and that the company will not receive proceeds from selling stockholders. The company may receive up to $3,900,000 if Aspire and Tailwinds warrants are exercised for cash; any proceeds are expected to be used for general working capital and corporate purposes.

Separately, the company disclosed a Compensation Committee action dated April 22, 2026 extending the expiration dates of outstanding options for the CEO (2,660,000 options) and CFO (870,550 options) from August 7, 2026 to August 7, 2029, which will result in an expected one-time non-cash share-based compensation charge of approximately $360,000.

ParkerVision, Inc. registers 18,014,164 shares of Common Stock for resale by selling stockholders under a prospectus supplement dated April 27, 2026.

The registration covers shares issuable upon conversion of convertible promissory notes across two tranches, shares issued for consulting services, and up to 1,800,000 shares issuable on a warrant with a $0.10 exercise price. The company will not receive proceeds from resales; if the Park Consulting Warrant is exercised for cash, the company would receive up to $180,000 to use for general working capital. The supplement attaches a Form 8-K reporting the Board Compensation Committee's approval to extend option expirations for two executives from August 7, 2026 to August 7, 2029, which will generate an estimated one-time, non-cash share-based compensation charge of approximately $360,000.

ParkerVision, Inc. files a Prospectus Supplement and attaches a Form 8-K to update its resale registration covering 17,189,660 shares of Common Stock. The supplement reconfirms resale registrations tied to prior private placements, a PIPE agreement with Aspire Capital, and convertible notes from 2018. The company will not receive proceeds from selling holders; issuer proceeds may occur only if certain warrants or PIPE-related instruments are exercised. The Form 8-K also discloses a Compensation Committee action to extend the expiration dates of previously awarded nonqualified stock options for CEO Jeffrey Parker (2,660,000 options) and CFO Cynthia French (870,550 options) from August 7, 2026 to August 7, 2029, with an unchanged exercise price of $0.171 per share. The company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 related to the modification.

ParkerVision, Inc. supplements its April 19, 2019 prospectus to register 12,800,000 shares of Common Stock for resale by selling stockholders, consisting of up to 7,800,000 shares issuable on conversion of convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant. The company will not receive proceeds from the resale; if the warrant is exercised for cash, the company would receive up to $800,000 to be used, if received, to fund patent enforcement actions and for general corporate purposes. The supplement also attaches a Form 8-K disclosing that the Compensation Committee approved an extension of the expiration dates of certain fully vested nonqualified stock options for the CEO and CFO from August 7, 2026 to August 7, 2029, which the company expects will result in a one-time non-cash share-based compensation charge of approximately $360,000.

ParkerVision, Inc. is registering for resale 9,387,500 shares of Common Stock under a prospectus supplement dated March 23, 2026, consisting of shares issued, shares issuable upon conversion of convertible notes, and shares issuable upon exercise of options.

The supplement states the company will not receive proceeds from selling shareholders; if the 200,000 Options are exercised for cash, the company would receive up to $42,620. The supplement attaches the company’s Form 10-K for the fiscal year ended December 31, 2025.

As context, shares outstanding were 147,535,024 as of March 19, 2026. The filing is a resale registration by selling holders under the existing Prospectus (Prospectus dated May 11, 2023).

ParkerVision, Inc. registers 16,638,353 shares of common stock for resale pursuant to a Prospectus Supplement dated March 23, 2026.

The shares are issuable upon conversion of convertible promissory notes dated between May 10, 2022 and August 3, 2022 at a fixed conversion price of $0.13 per share and are being resold by selling shareholders (resale offering). The Prospectus Supplement attaches the company’s Form 10-K for the fiscal year ended December 31, 2025 and updates disclosures.

Context: the company reported 147,535,024 shares outstanding as of March 19, 2026, cash and cash equivalents of $4.4M as of December 31, 2025, and convertible notes principal of $3.1M as of that date.

ParkerVision, Inc. registers 1,578,946 shares of Common Stock for resale under a prospectus supplement dated March 23, 2026. The registration consists of 1,052,631 shares of Common Stock and 526,315 shares issuable upon exercise of outstanding warrants. The company will not receive proceeds from resales by the selling stockholder; if the warrants are exercised for cash, ParkerVision would receive up to $526,315, which it expects to use for general working capital, including payment of litigation expenses.

The supplement incorporates ParkerVision’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and updates the prospectus’ disclosures regarding the company’s patent enforcement-focused business, contingent funding arrangements, convertible debt, and substantial doubt about its ability to continue as a going concern.

ParkerVision, Inc. is registering 13,342,953 shares of Common Stock for resale by selling stockholders under a prospectus supplement dated March 23, 2026.

The registered shares consist of 7,962,722 shares issued under earlier purchase agreements, 3,230,942 shares and 1,619,289 shares underlying warrants issued in March 2021, and 530,000 shares issued for services. The company will not receive proceeds from resale by the selling stockholders, but could receive up to $2,833,756 if the Warrants are exercised for cash; any such proceeds are expected to be used for general working capital, including payment of litigation expenses.

This prospectus supplement updates the Prospectus (dated April 26, 2021) with information from the Company’s Annual Report on Form 10-K filed March 23, 2026. Shares outstanding were 147,535,024 as of March 19, 2026.

ParkerVision, Inc. files a prospectus supplement to register the resale of 5,871,584 shares of Common Stock. The resale consists of shares issued under securities purchase agreements dated April 29, 2020 through August 19, 2020, and the company will receive no proceeds from sales by the selling stockholders.

The supplement attaches the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updates the base prospectus; it references patent-enforcement-driven licensing efforts, contingent funding arrangements, and going-concern disclosures in the attached Form 10-K.

ParkerVision, Inc. is registering 16,809,295 shares of its common stock for resale by the selling stockholders under a Prospectus Supplement dated March 23, 2026. The resale pool includes shares issuable on conversion of notes, shares issued under purchase agreements and as consideration, and shares issuable upon exercise of warrants.

The company states it will not receive proceeds from sales by the selling stockholders; however, if the Aspire and Tailwinds warrants are exercised for cash, the company would receive up to $3,900,000. Shares outstanding were 147,535,024 as of March 19, 2026.

ParkerVision, Inc. registers 18,014,164 shares of Common Stock for resale by selling stockholders under a prospectus supplement dated March 23, 2026. The registered shares consist of conversions of convertible notes, shares issued for services, and a warrant exercisable into up to 1,800,000 shares.

The company states it will not receive proceeds from sales by the selling stockholders; however, if the Park Consulting Warrant is exercised for cash the company would receive up to $180,000 in gross proceeds. This supplement attaches the company’s Form 10-K for the fiscal year ended December 31, 2025 and updates the prospectus with those disclosures.

ParkerVision, Inc. registered 17,189,660 shares of common stock for resale under a prospectus supplement dated March 23, 2026. The registration aggregates three groups: (i) 1,273,540 shares tied to a 2016 private placement and warrant, (ii) up to 10,000,000 shares issued/issuable under a July 26, 2018 PIPE agreement with Aspire Capital, and (iii) 5,916,120 shares issuable upon conversion of 2018 convertible notes at fixed conversion prices.

The supplement states the company will not receive proceeds from resales by selling stockholders; however, it may receive proceeds if the 2016 warrant or Aspire-issued warrants are exercised. The prospectus supplement incorporates the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and attaches that 10-K as an update.

ParkerVision, Inc. files a Prospectus Supplement registering 12,800,000 shares of Common Stock for resale by selling stockholders under its April 19, 2019 prospectus. The registration covers up to 7,800,000 shares issuable on conversion of certain convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant.

The company states it will not receive proceeds from resales by selling stockholders; if the warrant is exercised for cash, the company would receive up to $800,000 in gross proceeds, which it expects to use for patent enforcement and working capital. This supplement incorporates the Form 10-K filed March 23, 2026 and updates the Prospectus.

ParkerVision, Inc. filed a prospectus supplement dated March 13, 2026 updating its resale prospectus to register 9,387,500 shares of Common Stock for resale by selling shareholders. The supplement states the company will receive no proceeds from those resales; Option exercises could yield up to $42,620 in gross proceeds.

The supplement incorporates a Form 8-K reporting exchange agreements under which the company issued 3,277,099 shares on March 13, 2026 in exchange for cancellation of convertible notes with aggregate principal of $675,000 plus accrued interest.

ParkerVision filed a Prospectus Supplement registering 16,638,353 shares of Common Stock for resale, representing shares issuable upon conversion of previously disclosed convertible promissory notes at a fixed conversion price of $0.13 per share.

The supplement attaches a Form 8-K reporting that on March 13, 2026 the company completed exchange agreements under Section 3(a)(9), issuing an aggregate of 3,277,099 shares of Common Stock at an exchange price of $0.21 per share to cancel Exchange Notes with aggregate principal of $675,000 and accrued interest of approximately $13,200.

ParkerVision, Inc. filed a Prospectus Supplement registering the resale of 1,578,946 shares of common stock, consisting of 1,052,631 issued shares and 526,315 shares issuable upon exercise of warrants. The selling stockholder will receive proceeds from any resale; the company will not.

The supplement states the Company would receive up to $526,315 if the Warrants are exercised for cash and expects to use any proceeds for general working capital, including payment of litigation expenses. The supplement attaches a Form 8-K reporting that on March 13, 2026 the Company exchanged convertible notes for 3,277,099 shares at an exchange price of $0.21 per share in reliance on Section 3(a)(9), canceling notes with aggregate principal of $675,000 and accrued interest of approximately $13,200.

ParkerVision, Inc. registers 13,342,953 shares of Common Stock for resale under a prospectus supplement dated March 13, 2026. The resale registration covers shares held by selling stockholders and the company states it will not receive proceeds from those resales.

The supplement also attaches a Form 8-K reporting that the company issued an aggregate of 3,277,099 shares on March 13, 2026 in exchange for cancellation of convertible notes with aggregate principal of $675,000 and accrued interest of approximately $13,200 at an exchange price of $0.21 per share, using the Section 3(a)(9) exemption. The prospectus notes the company would receive up to $2,833,756 if certain warrants are exercised for cash.

ParkerVision, Inc. files a prospectus supplement registering 5,871,584 shares of Common Stock for resale by selling stockholders under its Prospectus dated September 2, 2020.

The supplement incorporates a Current Report on Form 8-K dated March 13, 2026, which reports that the company issued an aggregate of 3,277,099 shares of Common Stock on March 13, 2026 in exchange for cancellation of convertible promissory notes with an aggregate outstanding principal amount of $675,000 and accrued interest of approximately $13,200. The company states it will not receive proceeds from the resale of the registered shares.